The Application of Pyrrolo[2, 3-d]pyrimidine Scaffold in Medicinal Chemistry from 2017 to 2021

被引:3
作者
Liang, Ting [1 ]
Yang, Yingxiang [1 ]
Wang, Jiayun [1 ]
Xie, Zhao [1 ]
Chen, Xin [1 ]
机构
[1] Northwest A&F Univ, Coll Chem & Pharm, Shaanxi Key Labotory Nat Prod & Chem Biol, Yangling 712100, Peoples R China
基金
中国国家自然科学基金;
关键词
Pyrrolo[2; 3-d]pyrimidine; anti-inflammatory; IKKs; NIK; antibacterial; antitumor activities; KINASE; 2; LRRK2; T-CELL KINASE; THERAPEUTIC TARGET; BIOLOGICAL EVALUATION; SIGNALING PATHWAY; IN-VITRO; HIGHLY POTENT; KAPPA-B; INHIBITORS; DISCOVERY;
D O I
10.2174/1389557523666230111161810
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The application of privileged structures in drug design is an effective strategy, which usually leads to innovative hits/leads and successful structural optimization. Pyrrolo[2, 3-d]pyrimidine are such a scaffold which are frequently used in many clinical drugs. The biocompounds bearing pyrrolo[2, 3-d]pyrimidine skeleton show different pharmacological effects such as anti-neurodegenerative, anti-inflammatory, antibacterial, and antitumor activities. In this article, we reviewed the representative structures and biological characteristics of reported synthetic pyrrolo[2, 3-d]pyrimidine compounds from 2017 to 2021. The linked diseases and targets were also mentioned briefly. This work might provide a reference for the subsequent drug discovery based on pyrrolo[2, 3-d]pyrimidine scaffold.
引用
收藏
页码:1118 / 1136
页数:19
相关论文
共 150 条
  • [61] Novel and highly potent histamine H3 receptor ligands. Part 3: An alcohol function to improve the pharmacokinetic profile
    Labeeuw, Olivier
    Levoin, Nicolas
    Poupardin-Olivier, Olivia
    Calmels, Thierry
    Ligneau, Xavier
    Berrebi-Bertrand, Isabelle
    Robert, Philippe
    Lecomte, Jeanne-Marie
    Schwartz, Jean-Charles
    Capet, Marc
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (09) : 2548 - 2554
  • [62] Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation
    Lakkaniga, Naga Rajiv
    Gunaganti, Naresh
    Zhang, Lingtian
    Belachew, Binyam
    Frett, Brendan
    Leung, Yuet-Kin
    Li, Hong-yu
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 206
  • [63] Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach
    Lategahn, Jonas
    Hardick, Julia
    Grabe, Tobias
    Niggenaber, Janina
    Jeyakumar, Kirujan
    Keul, Marina
    Tumbrink, Hannah L.
    Becker, Christian
    Hodson, Luke
    Kirschner, Tonia
    Kloevekorn, Philip
    Ketzer, Julia
    Baumann, Matthias
    Terheyden, Susanne
    Unger, Anke
    Weisner, Joern
    Mueller, Matthias P.
    van Otterlo, Willem A. L.
    Bauer, Sebastian
    Rauh, Daniel
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (20) : 11725 - 11755
  • [64] Laurence Arian, 2012, Open Rheumatol J, V6, P232, DOI 10.2174/1874312901206010232
  • [65] Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors
    Lee, Ju-Hyeon
    Shin, Sang Chul
    Seo, Seon Hee
    Seo, Young Ho
    Jeong, Nakcheol
    Kim, Chan-Wha
    Kim, Eunice EunKyeong
    Keum, Gyochang
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (02) : 237 - 241
  • [66] Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
    Leonard, John P.
    LaCasce, Ann S.
    Smith, Mitchell R.
    Noy, Ariela
    Chirieac, Lucian R.
    Rodig, Scott J.
    Yu, Jian Q.
    Vallabhajosula, Shankar
    Schoder, Heiko
    English, Patricia
    Neuberg, Donna S.
    Martin, Peter
    Millenson, Michael M.
    Ely, Scott A.
    Courtney, Rachel
    Shaik, Naveed
    Wilner, Keith D.
    Randolph, Sophia
    Van den Abbeele, Annick D.
    Chen-Kiang, Selina Y.
    Yap, Jeffrey T.
    Shapiro, Geoffrey I.
    [J]. BLOOD, 2012, 119 (20) : 4597 - 4607
  • [67] ANTHRAX TOXIN EDEMA FACTOR - A BACTERIAL ADENYLATE-CYCLASE THAT INCREASES CYCLIC-AMP CONCENTRATIONS IN EUKARYOTIC CELLS
    LEPPLA, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (10): : 3162 - 3166
  • [68] Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity
    Li, Shunda
    Zhao, Chunlong
    Zhang, Guozhen
    Xu, Qifu
    Liu, Qian
    Zhao, Wei
    Chou, C. James
    Zhang, Yingjie
    [J]. BIOORGANIC CHEMISTRY, 2021, 116
  • [69] Discovery of &ITN&IT1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7&ITH&IT-pyrrolo[2,3-&ITd&IT]pyrimidin-2-yl)amino)phenyl)-&ITN&IT8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase 1 (HDAC1) against Malignant Cancer
    Li, Yongtao
    Luo, Xiaohe
    Guo, Qingxiang
    Nie, Yongwei
    Wang, Tianqi
    Zhang, Chao
    Huang, Zhi
    Wang, Xin
    Liu, Yanhua
    Chen, Yanan
    Zheng, Jianyu
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (07) : 3166 - 3192
  • [70] Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate
    Li, Yongtao
    Guo, Qingxiang
    Zhang, Chao
    Huang, Zhi
    Wang, Tianqi
    Wang, Xin
    Wang, Xiang
    Xu, Guangwei
    Liu, Yanhua
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (15) : 3231 - 3237